Non-Muscle Invasive Bladder Cancer Overview
Learn About Non-Muscle Invasive Bladder Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Robert Stockdale is an Urologist in Billings, Montana. Dr. Stockdale and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urothelial Cancer, and Ureteroscopy. Dr. Stockdale is currently accepting new patients.
Bozeman Health Deaconess Hospital
Gregory Pritham is an Urologist in Bozeman, Montana. Dr. Pritham and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Ureteroscopy, and Nephrectomy.
Billings Clinic
Lawrence Klee is an Urologist in Billings, Montana. Dr. Klee and is rated as a Distinguished provider by MediFind in the treatment of Non-Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Reconstruction, and Reconstructive Urology Surgery. Dr. Klee is currently accepting new patients.
Summary: This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from s...
Summary: This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P ...